Asahi Intecc, Dai-Dan, StemCell Institute and Taiko Pharmaceutical all took part in a $19.3m round for the cell-derived heart therapy developer.
Japan-based cell therapy developer Cuorips has raised ¥2bn ($19.3m) from investors including medical equipment producer Asahi Intecc, construction firm Dai-Dan, cord blood bank StemCell Institute and pharmaceutical firm Taiko Pharmaceutical.
Kyoto University Innovation Capital (KU-iCap), an investment vehicle for Kyoto University, filled out the round.
Founded in early 2017 as Cuore, the company was spun out by Osaka University and renamed Cuorips later in the year. It is working on a cell-derived therapy mainly composed of cardiomyocytes, the cells that…
